

APPENDIX I

IN THE CLAIMS:

Please cancel claims 1-8, and add the following claims:

- (9) A method of substantially returning work-related performance and/or workplace productivity of a person suffering from an allergic and/or inflammatory condition of the skin or airway passages to the person's baseline work-related performance or workplace productivity which comprises administering to said person an amount of desloratadine effective for such enhancing.
- (10) The method of claim 9 wherein the amount of desloratadine is about 2.5 mg/day to about 45 mg/day.
- (11) The method of claim 9 wherein the amount of desloratadine is about 5 mg/day to about 15 mg/day.
- (12) The method of claim 9 wherein the amount of desloratadine is about 5 mg/day to about 10 mg/day.
- (13) The method of claim 9 wherein the amount of desloratadine is about 5 mg/day.
- (14) The method of claim 9 wherein the allergic and/or inflammatory condition of the skin or airway passages is season allergic rhinitis, perennial allergic rhinitis, atopic dermatitis, urticaria or allergic asthma.

(15) A method of substantially returning work-related performance and/or workplace productivity of a person suffering from an allergic and/or inflammatory condition of the skin or airway passages to the person's baseline workplace productivity or workplace productivity which comprises administering to said person an amount of desloratadine effective for such returning.

(16) The method of claim 15 wherein the amount of desloratadine is about 2.5 mg/day to about 45 mg/day.

(17) The method of claim 15 wherein the amount of desloratadine is about 5 mg/day to about 15 mg/day.

(18) The method of claim 15 wherein the amount of desloratadine is about 5 mg/day to about 10 mg/day.

(19) The method of claim 15 wherein the amount of desloratadine is about 5 mg/day.

(20) The method of claim 15 wherein the allergic and/or inflammatory condition of the skin or airway passages is season allergic rhinitis, perennial allergic rhinitis, atopic dermatitis, urticaria or allergic asthma.

(21) A method of substantially returning workplace productivity of a person suffering from an allergic and/or inflammatory condition of the skin or airway passages productivity which comprises administering to said person an amount of desloratadine effective for such enhancing.

(22) The method of substantially returning workplace productivity of a person suffering from an allergic and/or inflammatory condition of the skin or airway passages to the person's baseline workplace productivity which comprises administering to said person an amount of desloratadine effective for such returning.

(23) The method of claim 22 wherein the amount of desloratadine is about 2.5 mg/day to about 45 mg/day.

(24) The method of claim 22 wherein the amount of desloratadine is about 5 mg/day to about 15 mg/day.

(25) The method of claim 22 wherein the amount of desloratadine is about 5 mg/day to about 10 mg/day.

(26) The method of claim 22 wherein the amount of desloratadine is about 5 mg/day.

(27) The method of claim 22 wherein the allergic and/or inflammatory condition of the skin or airway passages is season allergic rhinitis, perennial allergic rhinitis, atopic dermatitis, urticaria or allergic asthma.

(28) A method of substantially returning work-related performance of a person suffering from seasonal and/or perennial allergic rhinitis to the person's baseline work-related performance which comprises administering an amount of desloratadine to said person effective for such returning.

(29) The method of claim 28 wherein the amount of desloratadine is in the range of about 2.5 mg/day to about 45 mg/day.

(30) The method of claim 28 wherein the amount of desloratadine is about 5 mg/day to about 15 mg/day.

(31) The method of claim 28 wherein the amount of desloratadine is about 5 mg/day to about 10 mg/day.

(32) The method of claim 28 wherein the amount of desloratadine is about 5 mg/day.

(33) A method of substantially returning workplace productivity of a person suffering from seasonal and/or perennial allergic rhinitis to the person's baseline workplace productivity which comprises administering an amount of desloratadine to said person effective for such returning.

(34) The method of claim 33 wherein the amount of desloratadine is in the range of about 2.5 mg/day to about 45 mg/day.

(35) The method of claim 33 wherein the amount of desloratadine is about 5 mg/day to about 15 mg/day.

(36) The method of claim 33 wherein the amount of desloratadine is about 5 mg/day to about 10 mg/day.

(37) The method of claim 33 wherein the amount of desloratadine is about 5 mg/day.

(38) A method of substantially returning work-related performance of a person suffering from atopic dermatitis and/or urticaria to the person's baseline work-related performance which comprises administering an amount of desloratadine effective for such returning.

(39) The method of claim 38 wherein the amount of desloratadine is about 2.5 mg/day to about 45 mg/day.

(40) The method of claim 38 wherein the amount of desloratadine is about 5 mg/day to about 15 mg/day.

(41) The method of claim 38 wherein the amount of desloratadine is about 5 mg/day to about 10 mg/day.

(42) The method of claim 38 wherein the amount of desloratadine is about 5 mg/day.

(43) The method of claim 38 wherein the patient is suffering from atopic dermatitis.

(44) The method of claim 38 wherein the patient is suffering from urticaria.

(45) A method of substantially returning workplace productivity of a person suffering from atopic dermatitis and/or urticaria to the person's baseline workplace productivity

which comprises administering an amount of desloratadine to said person effective for such returning.

(46) The method of claim 45 wherein the amount of desloratadine is about 2.5 mg/day to about 45 mg/day.

(47) The method of claim 45 wherein the amount of desloratadine is about 5 mg/day to about 15 mg/day.

(48) The method of claim 45 wherein the amount of desloratadine is about 5 mg/day to about 10 mg/day.

(49) The method of claim 45 wherein the amount of desloratadine is about 5 mg/day.

(50) The method of claim 45 wherein the patient is suffering from atopic dermatitis.

(51) The method of claim 45 wherein the patient is suffering from urticaria.

(52) A method of substantially returning work-related performance of a person suffering from an allergic and/or inflammatory condition of the skin or lower airway passages to the person's baseline work-related performance which comprises administering to said person an initial amount of desloratadine effective for such returning.

(53) The method of claim 52 wherein the amount of desloratadine is about 5 mg/day.

(54) A method of substantially returning workplace productivity of a person suffering from an allergic and/or inflammatory condition of the skin or lower passages to the person's baseline workplace productivity which comprises administering an initial amount of desloratadine to said person effective for such returning.

(55) The method of claim 54 wherein the amount of desloratadine is about 5 mg/day.

20250629 10:03:00